Patents Examined by Oluwatosin Ogunbiyi
  • Patent number: 11066464
    Abstract: Antibodies that bind to the circumsporozoite protein (CSP) of Plasmodium falciparum. Use of such antibodies as anti-malarial agents, to confer protection against infection by malarial parasites such as P. falciparum by insect vector transmission. Diagnosis of malaria using anti-CSP antibodies. Methods of determining efficacy of candidate vaccine compositions in development and testing of anti-malarial vaccines.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: July 20, 2021
    Inventors: Qi Liang, Sean Matthew Carroll, Daniel Eric Emerling, Allan Bradley, Paul Kellam, {hacek over (S)}pela Binter, Simon James Watson
  • Patent number: 11052142
    Abstract: For the first time individual (free from impurities of penta- and hexa-acetylated derivatives) di-, tri- and tetra-acetylated S-LPS of endotoxic bacteria and combinations thereof were obtained and their immunobiological, physical-chemical and chemical-pharmaceutical properties were studied. For the first time the principal possibility of their clinical application was directly demonstrated as vaccines and pharmaceutical compositions containing the modified S-LPS individual as monocomponent or combinations thereof as two and three component active substance, respectively. The modified S-LPS and combinations thereof have high safety profile and provide low pyrogenicity and high immunogenicity. Developed on their basis vaccines and pharmaceutical compositions demonstrate anti-shock activity, high efficiency and specificity, broad-spectrum action and also good chemical-pharmaceutical parameters.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: July 6, 2021
    Inventors: Petr Gennadievich Aparin, Vyacheslav Leonidovich Lvov, Stanislava Ivanovna Elkina, Marina Eduardovna Golovina
  • Patent number: 11052121
    Abstract: The invention relates to the use of a bacterial mixture for the prevention and improvement of the state of ungulates suffering from pathologies involving a parasitic or bacterial infection of the foot, said composition comprising: at least one strain of bacteria of the genus Bacillus, and at least one lactic acid bacterium.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: July 6, 2021
    Assignee: Nolivade
    Inventors: Michel Layus, Alexandre Brame
  • Patent number: 11015182
    Abstract: The present disclosure relates to chimeric bacteriophage lysins useful for the identification and/or reduction of staphylococcal populations. For example, a chimeric bacteriophage lysin was engineered and shown to effectively kill all strains of staphylococci tested including antibiotic resistant methicillin-resistant S. aureus (MRSA) and vancomycin intermediate S. aureus (VISA).
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: May 25, 2021
    Assignee: The Rockefeller University
    Inventors: Vincent A. Fischetti, Anu Daniel, Chad Euler
  • Patent number: 10988792
    Abstract: The present invention relates to methods and systems for determining the antibiotic-resistance status of microorganisms. The invention further provides methods for determining the antibiotic-resistance status of microorganisms in situ within a single system.
    Type: Grant
    Filed: November 2, 2015
    Date of Patent: April 27, 2021
    Assignee: bioMerieux, Inc.
    Inventors: John Walsh, Jones Hyman
  • Patent number: 10975377
    Abstract: The present disclosure relates to a method for regulating expression of protein of interest in Bacillus subtilis, and belongs to the technical field of genetic engineering. The method comprises: using Bacillus subtilis as an expression host, adding the N-terminal nucleotide sequence coding the first 15 amino acids of the endogenous protein before the coding gene of the protein of interest or modifying the original N-terminal nucleotide sequence coding the first 15 amino acids, and performing free expression in plasmid, thereby regulating expression of the protein of interest in Bacillus subtilis, and even regulating the expression difference in different growth phases and the expression level.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: April 13, 2021
    Inventors: Yanfeng Liu, Guocheng Du, Rongzhen Tian, Jian Chen
  • Patent number: 10973245
    Abstract: This invention relates to a composition for additives which can be employed in animal feeds, or as growth promoters, or as nutraceuticals, or as prebiotics, or as additives for the control and prophylaxis of pathogenic bacteria in the intestinal tract of animals or farmed animals. An immunomodulatory and promoter composition for controlling the population of undesirable bacteria of the intestinal microbiota, comprising the components indicated below: (a) Fructooligosaccharides (FOS); (b) Galacto-oligosaccharides (GOS); (c) Mannan-oligosaccharides (MOS); (d) 1,3 and 1,6 Beta-glucans.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: April 13, 2021
    Inventor: Victor Abou Nehmi Filho
  • Patent number: 10961299
    Abstract: Novel, antibody-based binding agents derived from human and camelid immunoglobulins are described. These binding agents recognize and bind with specificity to Clostridium difficile toxin A and/or toxin B and in some cases exhibit toxin neutralizing activity. These binding agents can be used to treat or prevent primary and recurrent CDI. The binding agents include camelid VHH peptide monomers, linked groups of VHH peptide monomers, VHH peptide monomers joined to antibody Fc domains, and VHH peptide monomers joined to IgG antibodies.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: March 30, 2021
    Assignee: University of Maryland, Baltimore
    Inventors: Hanping Feng, Yongjun Guan, Yongrong Zhang, Zhiyong Yang, Lianfa Shi
  • Patent number: 10933128
    Abstract: A method and system for the treatment of honey bees (Apis mellifera), bats, and butterflies protects them from various life threatening conditions, including Colony Collapse Disorder, white nose syndrome, etc. and in particular, provides honey bees, bats and butterflies with the ability to assimilate and degrade pesticides such as neonicotinoids and fipronil.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: March 2, 2021
    Inventor: Joseph E. Kovarik
  • Patent number: 10925945
    Abstract: The present invention relates to the preparation and use in primates of whole organismvaccines in which the MEP pathway is disrupted such that synthesis of HMBPP by the bacterial cells is substantially blocked. The data provided demonstrates that, when bacteria or other vaccine vectors that comprise an active MEP pathway are used in vaccine methods, the ?? T cell response dominates, potentially clearing the vaccine strain via ?? T cell-mediated killing of vector infected antigen presenting cells and reducing its utility as a stimulator of a productive adaptive immune response, specifically priming or boosting of CD4+ and CD8+ ?? T cell responses, specific for listerial-encoded antigens. By disrupting the MEP pathway, activation and expansion of ?? T cells is limited in the recipient primate, resulting in resulting in an increase in the magnitude and duration of inflammation and in the magnitude and duration of antigen presentation by the cellular vaccine.
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: February 23, 2021
    Inventors: Keith Bahjat, Yoshinobu Koguchi, Alejandro F. Alice
  • Patent number: 10919942
    Abstract: The present application relates to the use of bacterial minicells as targeted delivery agents in vivo and in vitro. Described herein are genetically engineered eubacterial minicells designed to preferentially target and deliver therapeutically relevant agents using a minicell surface coupling molecule capable of binding and displaying antibodies or other Fc-containing targeting moiety fusions and conjugates.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: February 16, 2021
    Inventors: Matthew J. Giacalone, Michael J. Newman
  • Patent number: 10918677
    Abstract: The present invention provides attenuated or inactivated pathogenic bacteria having anti-cancer properties, compositions comprising the bacteria, and use thereof for treating cancers of the urogenital system.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: February 16, 2021
    Inventors: Ofer Mandelboim, Gilad Benjamin Bachrach, Chamutal Gur, Vladimir Yutkin
  • Patent number: 10920212
    Abstract: The present invention discloses a procedure to produce a monomeric and functional form of Bordetella sp, especially B. pertussis, CyaA toxin that can be stably maintained in this functional monodisperse state, even in the absence of any chaotropic agent.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: February 16, 2021
    Inventors: Alexandre Chenal, VĂ©ronique Ntsogo Enguene, Audrey Hessel, Johanna Karst-Spiaczka, Daniel Ladant
  • Patent number: 10883079
    Abstract: Microparticles include a matrix of an encapsulating material, in which are dispersed particles of a low melting point fat and a bioactive material, such as one or more probiotic bacteria. The microparticles are formed by preparing an emulsion of melted low melting point fat in an aqueous mixture of the encapsulating material, cooling the emulsion below the melting point of the low melting point fat, dispersing the bioactive material in the emulsion and spray drying the emulsion. The particles of solid low melting point fat are believed to protect the bioactive material from heat damage during the spray drying process.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: January 5, 2021
    Inventors: Qi Wang, Huan Liu, Jianhua Gong, Hai Yu, Qian Guo, Shea Miller, Wuwei Cui
  • Patent number: 10883989
    Abstract: Provided are peptides suitable for early detection of active M. tuberculosis (Mtb) infection in immunocompromised individuals. The peptides can form complexes with antibodies directed to Mtb antigens MS, MPT51, ESAT6 or CFPIO. Also provided are methods for detected of complexes of the peptides and the antibodies. The presence of complexes aids in predicting risk in immunocompromised individuals of developing active tuberculosis.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: January 5, 2021
    Assignee: New York University
    Inventor: Suman Laal
  • Patent number: 10881696
    Abstract: Provided are therapeutic compositions containing combinations of bacteria, for the maintenance or restoration of a healthy microbiota in the gastrointestinal tract of a mammalian subject, and methods for use thereof.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: January 5, 2021
    Assignee: Seres Therapeutics, Inc.
    Inventors: Matthew R. Henn, David N. Cook, Toshiro K. Ohsumi, Mary-Jane Lombardo McKenzie, Kevin D. Litcofsky, Han Zhang, John Grant Aunins, David Arthur Berry
  • Patent number: 10870894
    Abstract: Methods for detecting microorganisms, in particular detection of bacteria and methods for measuring enzyme activity, such as Deoxyribonucleic acid (DNA) polymerase activity are disclosed. The aforesaid methods include, but are not limited to such methods performed on microbial crude lysates, useful for determining microbial enzyme activities, which can be linked to amplification signal generators such as real-time Polymerase Chain Reaction (PCR) techniques, thereby enabling determination of microbial pathogens in samples such as unpurified blood and other body fluids. Moreover, the disclosed embodiments also relate to reagents for use in such methods, and to test kits comprising such reagents for carrying out the methods.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: December 22, 2020
    Inventors: Shawn Mark O'Hara, Daniel Zweitzig
  • Patent number: 10869918
    Abstract: The present application provides methods and uses of O-oligosaccharyltransferase (O-OTases) for generating vaccines. In particular, the present application provides a method of synthesizing a glycoprotein comprising glycosylation of pilin-like protein ComP using a PglLComP O-OTase. Uses of glycoproteins synthesized by glycosylating ComP using PglLComP O-OTase, particularly for the preparation of vaccines and the like, including a vaccine to Streptococcus, is also provided.
    Type: Grant
    Filed: April 22, 2019
    Date of Patent: December 22, 2020
    Assignee: VAXNEWMO LLC
    Inventors: Mario Feldman, Mohamed Adel Nasr
  • Patent number: 10851136
    Abstract: The present invention relates to an oral universal influenza vaccine comprising recombinant lactic acid bacteria which express proteins including but not limited to ferritin protein plus highly-conserved stem fragment of hemagglutinin (HA) proteins expressed in all known influenza viruses. The present invention also relates to the recombinant protein comprising the highly-conserved stem fragment of HA and ferritin proteins.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: December 1, 2020
    Inventors: Chung Yan Shum, Tak Keung Andy Wong
  • Patent number: 10835601
    Abstract: Disclosed herein is a vaccine comprising an antigen and a protein, peptide, or carbohydrate of Chlamydia spp., or a fragment thereof, wherein the antigen is not derived from a Chlamydia spp. Also disclosed are methods of treating or preventing diseases comprising administering to a subject a vaccine, wherein the vaccine comprises an antigen and a protein, peptide, or carbohydrate of Chlamydia spp., or a fragment thereof, wherein the antigen is not derived from a Chlamydia spp.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: November 17, 2020
    Assignee: Ohio State Innovation Foundation
    Inventors: Thomas Cherpes, Nirk E. Quispe Calla, Rodolfo Daniel Vicetti Miguel